Ascendis Pharma A/S
ASND
102 hedge funds and large institutions have $2.63B invested in Ascendis Pharma A/S in 2018 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 30 reducing their positions, and 8 closing their positions.
449% more call options, than puts
Call options by funds: $32.5M | Put options by funds: $5.92M
138% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 8
27% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 30
11% more funds holding
Funds holding: 92 → 102 (+10)
5% more capital invested
Capital invested by funds: $2.49B → $2.63B (+$136M)
3.48% more ownership
Funds ownership: 91.83% → 95.31% (+3.5%)
14% less funds holding in top 10
Funds holding in top 10: 14 → 12 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$68.8M |
| 2 |
LCM
Lakewood Capital Management
New York
|
+$29.6M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$27.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.5M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$25.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$23.6M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$23M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$15.3M |
| 5 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$13.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
DZ Bank
Frankfurt Am Main,
Germany
| – | -$1.24M | -19,000 | Closed |
|
102
Neuberger Berman Group
New York
| – | -$916K | -14,000 | Closed |
|
103
Tudor Investment Corp
Stamford,
Connecticut
| – | -$766K | -11,705 | Closed |
|
104
JP Morgan Chase
New York
| – | -$256K | -3,899 | Closed |
|
105
Jane Street
New York
| – | -$250K | -3,817 | Closed |
|
|
VF
106
Virtu Financial
New York
| – | -$227K | -3,478 | Closed |
|
|
APP
107
Avantax Planning Partners
Dubuque,
Iowa
| – | -$13K | -200 | Closed |
|
108
Citigroup
New York
| – | -$9K | -142 | Closed |
|
|
FGAM
109
Financial Gravity Asset Management
Lakeway,
Texas
| – | -$66 | -1 | -33% |
|
110
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$66 | -1 | -25% |
|
ASND Hedge Fund Activity: Q2 2018 in Review
102 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2018, worth a combined $2.63B — up 5.4% from $2.49B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ASND positions and 8 closed out — a net gain of 11 holders — while 38 added to existing stakes and 30 trimmed.
The largest buyer was OrbiMed, adding an estimated $68.8M. The largest seller was Fidelity Investments, cutting an estimated $25.3M.
- 102 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2018, up from 92 in Q1 2018.
- Funds reported $2.63B of Ascendis Pharma A/S stock for Q2 2018, up 5.4% quarter-over-quarter.
- 19 funds opened new Ascendis Pharma A/S positions in Q2 2018 and 8 closed out, a net change of +11 holders.
- The largest Ascendis Pharma A/S buyer in Q2 2018 was OrbiMed, an estimated $68.8M added.
- The largest Ascendis Pharma A/S seller in Q2 2018 was Fidelity Investments, an estimated $25.3M sold.
Based on aggregated 13F filings for Q2 2018.